TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a...
Vous n'êtes pas connecté
Investigators analyzing the potential cognitive effects of antidiabetic medications in records of more than 1.5 million patients with type 2 diabetes mellitus (T2DM) found risks of dementia and Alzheimer's disease (AD) were significantly lower in patients treated with metformin and sodium glucose co-transporter-2 inhibitors (SGLT-2i) compared to other antidiabetic drugs.
TUESDAY, Sept. 3, 2024 -- Sodium-glucose cotransporter-2 (SGLT-2) inhibitors may prevent dementia in middle-aged adults with diabetes, according to a...
A recent study from Korea, published in The BMJ, suggests that certain diabetes drugs, specifically sodium-glucose cotransporter-2 (SGLT-2)...
Large Korean study suggests sodium-glucose cotransporter-2 inhibitors may lower the risk of dementia
A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be at a significantly lower...
A Korean study published recently suggests people with type 2 diabetes who are prescribed a particular class of drug might be at a significantly lower...
New research has found a way to diagnose Alzheimer’s disease (AD) earlier by analyzing biomarkers in blood. This could help reduce the effects of...
WEDNESDAY, Aug. 28, 2024 -- Cholinesterase inhibitors (ChEIs) are beneficial for patients with dementia with Lewy bodies (DLB), according to a study...
Sodium-glucose cotransporter-2 (SGLT2) inhibitors, a newer class of drugs used to manage diabetes, have recently been linked to a rare but serious...
Cognitive decline and dementia can be caused by illnesses like Alzheimer’s disease and conditions like high blood pressure, which damage blood...
Nearly 500 million adults worldwide are living with type 2 diabetes, and over 200 million of them take metformin, a common medication that helps lower...